Latest News

Shadow health minister Catherine King says Greg Hunt has "contradicted the evidence of his own department about the role his office played in the GIOTRIF drug deal."

A head-to-head debate over PBS policy in the federal parliament this week with disputed claims over savings, spending and new listings.

Still no clarity on the preferred model for implementation of the reform of supply chain arrangements for PBS-listed medicines with special pricing arrangements.

Another managing director is departing with the added complication of a vacancy on the Medicines Australia Board.

Many in industry harbour residual frustration over what they believe was a process compromised by an impractically short timeline. Yet not all companies waited for an established process before acting.

Australia may have avoided making a detailed commitment on extending data protection for biologics in the Trans-Pacific Partnership Agreement but the issue will almost certainly be raised as part of negotiations for a new free trade agreement with the EU.

A big week for AbbVie as the company's Australian employees take part in its global 'Week of Possibilities' event.

A busy day for Medicines Australia with a member company briefing in Melbourne, an important meeting in Sydney to discuss the reform of supply chain arrangements, and then an evening event in Canberra involving senior Turnbull government ministers.

Recent evidence suggests companies wanting a special pricing arrangement might be better off choosing direct negotiation with the Department of Health instead of navigating the PBAC process.

Novartis' generics and biosimilar division Sandoz has released the results of two significant phase 3 biosimilar switching studies.

The 1 July PBS schedule update has confirmed the previously announced listing of Novartis' KISQALI (ribociclib), a streamlined authority for the biosimilar brands of infliximab and a new adrenaline auto-injector.

The Generic and Biosimilar Medicines Association has announced the appointment of a new project manager for its educational arm, GBMA Education, to drive implementation of its $5 million biosimilar grant.